19、Rugo,Hope S et al.“Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer(TROPiCS-02):a randomised,open-label,multicentre,phase 3 trial.”Lancet(Lon...
[1]Burstein HJ. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020 Dec 24;383(26):2557-2570. [2]Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. ...
20、Binghe Xu,et al.Sacituzumab govitecan(SG)vs treatment of physician’s choice(TPC)in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative(HR+/HER2–)metastatic breast cancer(mBC):Results from the phase III EVER-002 study.2023 ESMO asia Abstracts...
Breast cancer patients with high proportion of cancer stem cells (BCSCs) have poor clinical outcomes. MiRNAs regulate key features of BCSCs as oncogenes or tumor suppressors. Although hormone receptor (HR)-positive, HER2-negative breast cancers are the most common subtype, current methods are inad...
[4].Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, et al. Firstline treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positivemetastatic breast cancer from registHER. Oncologist 2013;18:501–10.[5].Rimawi M, Ferrero JM, de la ...
[6] Sheffield KM, Peachey JR, Method M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022 Jul;18(21):2...
2023年9月,我带领的团队在Nature Genetics发表了“Molecular classification of hormone receptor-positive HER2-negative breast cancer”的文章,公布了HR+/HER2-乳腺癌的复旦分型[17]。我们团队通过建立579例HR+/HER2-乳腺癌患者的大规模多组学队列,确定了以下四种分子亚型:经典管腔型、免疫原性型、增殖型、受体酪氨酸...
2023年8月17日,Annals of Oncology期刊(IF:50.5)在线发表题为“Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial”的文章,纪念斯隆-凯特琳癌症中心/威尔·康奈尔医学院K Jhaveri为第一和通讯作者。
[8] Turner NC, et al.Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:results from the Phase III CAPItello-291 trial.2022 SABCS.GS3-04. ...
2%）。参考来源：‘Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer’，新闻稿。AstraZeneca；2024年4月2日发布。注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。